Literature DB >> 28626530

Discovery of a Series of Indazole TRPA1 Antagonists.

David C Pryde1, Brian E Marron2, Christopher W West2, Steven Reister2, George Amato2, Katrina Yoger2, Brett Antonio2, Karen Padilla2, Peter J Cox1, Jamie Turner1, Joseph S Warmus3, Nigel A Swain1, Kiyoyuki Omoto1, John H Mahoney2, Aaron C Gerlach2.   

Abstract

A series of TRPA1 antagonists is described which has as its core structure an indazole moiety. The physical properties and in vitro DMPK profiles are discussed. Good in vivo exposure was obtained with several analogs, allowing efficacy to be assessed in rodent models of inflammatory pain. Two compounds showed significant activity in these models when administered either systemically or topically. Protein chimeras were constructed to indicate compounds from the series bound in the S5 region of the channel, and a computational docking model was used to propose a binding mode for example compounds.

Entities:  

Keywords:  AITC; Cinnamaldehyde flare; Indazole; Ion channel; Pain; TRPA1; Topical administration; Transient receptor potential

Year:  2017        PMID: 28626530      PMCID: PMC5467201          DOI: 10.1021/acsmedchemlett.7b00140

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  13 in total

Review 1.  Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine.

Authors:  Bernd Nilius; Arpad Szallasi
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

2.  Development of a new permeability assay using low-efflux MDCKII cells.

Authors:  Li Di; Carrie Whitney-Pickett; John P Umland; Hui Zhang; Xun Zhang; David F Gebhard; Yurong Lai; James J Federico; Ralph E Davidson; Russ Smith; Eric L Reyner; Caroline Lee; Bo Feng; Charles Rotter; Manthena V Varma; Sarah Kempshall; Katherine Fenner; Ayman F El-Kattan; Theodore E Liston; Matthew D Troutman
Journal:  J Pharm Sci       Date:  2011-07-15       Impact factor: 3.534

3.  Selective blockade of TRPA1 channel attenuates pathological pain without altering noxious cold sensation or body temperature regulation.

Authors:  Jun Chen; Shailen K Joshi; Stanley DiDomenico; Richard J Perner; Joe P Mikusa; Donna M Gauvin; Jason A Segreti; Ping Han; Xu-Feng Zhang; Wende Niforatos; Bruce R Bianchi; Scott J Baker; Chengmin Zhong; Gricelda H Simler; Heath A McDonald; Robert G Schmidt; Steve P McGaraughty; Katharine L Chu; Connie R Faltynek; Michael E Kort; Regina M Reilly; Philip R Kym
Journal:  Pain       Date:  2011-03-12       Impact factor: 6.961

4.  Identification of transmembrane domain 5 as a critical molecular determinant of menthol sensitivity in mammalian TRPA1 channels.

Authors:  Bailong Xiao; Adrienne E Dubin; Badry Bursulaya; Veena Viswanath; Timothy J Jegla; Ardem Patapoutian
Journal:  J Neurosci       Date:  2008-09-24       Impact factor: 6.167

5.  Identification of molecular determinants for a potent mammalian TRPA1 antagonist by utilizing species differences.

Authors:  Kazumasa Nakatsuka; Rupai Gupta; Shigeru Saito; Nagako Banzawa; Kenji Takahashi; Makoto Tominaga; Toshio Ohta
Journal:  J Mol Neurosci       Date:  2013-07-20       Impact factor: 3.444

Review 6.  TRPA1 as a drug target--promise and challenges.

Authors:  Jun Chen; David H Hackos
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-02-03       Impact factor: 3.000

7.  Structure of the TRPA1 ion channel suggests regulatory mechanisms.

Authors:  Candice E Paulsen; Jean-Paul Armache; Yuan Gao; Yifan Cheng; David Julius
Journal:  Nature       Date:  2015-04-08       Impact factor: 49.962

8.  The pore-domain of TRPA1 mediates the inhibitory effect of the antagonist 6-methyl-5-(2-(trifluoromethyl)phenyl)-1H-indazole.

Authors:  Hans Moldenhauer; Ramon Latorre; Jörg Grandl
Journal:  PLoS One       Date:  2014-09-02       Impact factor: 3.240

9.  A gain-of-function mutation in TRPA1 causes familial episodic pain syndrome.

Authors:  Barbara Kremeyer; Francisco Lopera; James J Cox; Aliakmal Momin; Francois Rugiero; Steve Marsh; C Geoffrey Woods; Nicholas G Jones; Kathryn J Paterson; Florence R Fricker; Andrés Villegas; Natalia Acosta; Nicolás G Pineda-Trujillo; Juan Diego Ramírez; Julián Zea; Mari-Wyn Burley; Gabriel Bedoya; David L H Bennett; John N Wood; Andrés Ruiz-Linares
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

10.  Transient receptor potential ankyrin 1 receptor activation in vitro and in vivo by pro-tussive agents: GRC 17536 as a promising anti-tussive therapeutic.

Authors:  Indranil Mukhopadhyay; Abhay Kulkarni; Sarika Aranake; Pallavi Karnik; Mahesh Shetty; Sandeep Thorat; Indraneel Ghosh; Dinesh Wale; Vikram Bhosale; Neelima Khairatkar-Joshi
Journal:  PLoS One       Date:  2014-05-12       Impact factor: 3.240

View more
  3 in total

1.  TRPA1 ankyrin repeat six interacts with a small molecule inhibitor chemotype.

Authors:  Wei Chou Tseng; David C Pryde; Katrina E Yoger; Karen M Padilla; Brett M Antonio; Seungil Han; Veerabahu Shanmugasundaram; Aaron C Gerlach
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-14       Impact factor: 11.205

2.  Computational Drug Repurposing Algorithm Targeting TRPA1 Calcium Channel as a Potential Therapeutic Solution for Multiple Sclerosis.

Authors:  Dragos Paul Mihai; George Mihai Nitulescu; George Nicolae Daniel Ion; Cosmin Ionut Ciotu; Cornel Chirita; Simona Negres
Journal:  Pharmaceutics       Date:  2019-09-02       Impact factor: 6.321

Review 3.  Recent Advances in Indazole-Containing Derivatives: Synthesis and Biological Perspectives.

Authors:  Shu-Guang Zhang; Chao-Gen Liang; Wei-Hua Zhang
Journal:  Molecules       Date:  2018-10-26       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.